Interpretation of Lung Cancer PlasmaEGFRMutation Tests in the Clinical Setting

Alvin H.k. Cheung, Kit Yee Wong, Cho‐Han Chiang, Xiaoli Liu, Yihan Zhang, Chris Ho‐Lam Hui, Bonan Chen, Yifei Wang, Chit Chow, Wei Kang, Ka‐Fai ToAmerican 2022 · DOI

Abstract

While interpreting plasma EGFR mutation results, extra caution should be exercised for patients with early-stage, localized disease to accommodate the possibility of false-negative results. These meta-analyses and clinical data may enable clinicians to make evidence-based judgments for individual patients.
BibTeX
@inproceedings{cheung2022interpretation,
  author = {Alvin H.K. Cheung and Kit Yee Wong and Cho‐Han Chiang and Xiaoli Liu and Yihan Zhang and Chris Ho‐Lam Hui and Bonan Chen and Yifei Wang and Chit Chow and Wei Kang and Ka‐Fai To},
  title = {{Interpretation of Lung Cancer Plasma<i>EGFR</i>Mutation Tests in the Clinical Setting}},
  booktitle = {American},
  year = {2022},
  doi = {10.1093/ajcp/aqac149},
}

Loading related content...

Figure